Charles Stent Charles Stent Charles Stent (1807–1885) was a 19th-century English dentist notable for his advances in the field of denture making. In 1847, Edwin Truman introduced gutta-percha as a material for making dental impressions; however, this was unsatisfactory for several reasons, including its tendency to distort upon removal from the patient's mouth, and to shrink upon cooling. In 1856, Stent added several other materials to the gutta-percha, notably stearine, which markedly improved the plasticity of the material as well as its stability. He also added talc as an inert filler to give more body to the material, and red colouring. The
Drug-eluting stent to bring a bioresorbable stent to market was Abbott Vascular which received a European marketing approval in September 2012; the second was Elixir which received its CE mark in May 2013. In 2017, Abbot pulled its bioabsorbable stent, Absorb, from the European market after negative press regarding the device. Boston Scientific also announced termination of its Renuvia bioresorbable coronary stent program as studies showed higher risk of serious adverse events. In 2012, a meta-analysis of clinical trial data was published, showing that, for people with stable coronary artery disease, DES has no benefit compared to treatment with drugs. The New